Some randomized trials have tested probiotics in hepatobiliary tumors and have shown an increase in TNFα and IL1β in the postoperative period, supporting the use of probiotics to modulate the immune response and reduce infectious complications in patients. This evidence concerns the gene IL1B and hepatobiliary neoplasm.